|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.91 USD | +2.25% |
|
-1.92% | -33.91% |
| 05-07 | MoonLake Immunotherapeutics Q1 Net Loss Widens | MT |
| 05-07 | MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
MoonLake Immunotherapeutics reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 13.67 million compared to USD 9 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.23 a year ago.
Diluted loss per share from continuing operations was USD 0.22 compared to USD 0.23 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -33.91% | 2.45B | |
| +9.99% | 114B | |
| +12.01% | 107B | |
| -3.07% | 22.22B | |
| -0.67% | 21.28B | |
| -4.64% | 18.8B | |
| -6.90% | 17.51B | |
| -39.36% | 17.17B | |
| +5.82% | 14.14B | |
| +33.05% | 12.2B |
MOONLAKE IMMUNOTHERAPEUTICS 
